28th August 2020
- 0 comments
Maven Capital Partners, one of the UK’s most active private equity managers, has invested £1.5 million in Gen inCode, a genetic testing business specialising in the risk assessment and prediction of cardiovascular disease. Gen inCode raised in total £3.4 million, where Maven invested alongside another institutional investor and existing private shareholders.
In order to read the full story we need you to be registered with us, please click the links below to login or register.